Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/IIa Study Assessing Single and Multiple Doses of Hepatitis C Virus (HCV) Protease Inhibitor IDX320 in Healthy and Genotype 1 HCV-Infected Subjects.

Trial Profile

A Phase I/IIa Study Assessing Single and Multiple Doses of Hepatitis C Virus (HCV) Protease Inhibitor IDX320 in Healthy and Genotype 1 HCV-Infected Subjects.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 25 Jul 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IDX 320 (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 26 Oct 2011 Results will be presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2011)
    • 01 Nov 2010 Results were presented at the 61st Annual Meeting of the American Association for the Study of Liver Diseases.
    • 07 Sep 2010 Status changed from recruiting to completed. According to an Idenix media release, all planned studies of IDX 320 to date have been completed and there are currently no healthy volunteers or patients receiving this drug.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top